 | |
| Clinical data | |
|---|---|
| Other names | JZP-150; JZP150; PF-04457845; PF-4457845; PF04457845; PF4457845 |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | CY3A4 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H20F3N5O2 |
| Molar mass | 455.441 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Redafamdastat (INNTooltip International Nonproprietary Name; developmental code namesJZP-150,PF-04457845) is aninhibitor of theenzymefatty acid amide hydrolase (FAAH), with anIC50Tooltip half-maximal inhibitory concentration of 7.2 nM, and bothanalgesic andanti-inflammatory effects inanimal studies comparable to those of thecyclooxygenase inhibitornaproxen.[1] It was being developed byJazz Pharmaceuticals for the treatment ofalcoholism,pain, andpost-traumatic stress disorder (PTSD) and reachedphase 2clinical trials.[2][3] However, development of the drug was discontinued in December 2023.[2]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
